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The operational definition of “sarcopenia”, an age-related skeletal muscle disease resulting from
adverse changes that accrue across the lifetime, was recently updated by the European Working Group
on Sarcopenia in Older People (EWGSOP) [1]. The revised definition differs from the original in
terms of suggested measurements, cut-off points and case-finding algorithms. Consequently, reported
sarcopenia prevalence estimates have drastically changed since the publication of this definition [2]
and further investigation of the impacts of the revision are warranted in diverse populations.
A recent article by Su et al., published in the Journal of Clinical Medicine, explores the prevalence
of sarcopenia in older adults residing on the northern island of Hokkaido, Japan, which is described by
the authors as “cold and snowy in the winter, with the roads covered with snow from November to
April” [3]. This in an interesting population in which to investigate sarcopenia prevalence given that
older adults living in colder climates may have increased likelihood for sarcopenia.
There are several mechanisms by which residing in colder climates may exacerbate age-related
muscle declines. In particular, it has been hypothesised that the presence of snow and icy conditions
may increase older adults’ fear of falling and subsequently restrict physical activity [4]. A study of
community-dwelling Scottish older adults, however, reported that presence of snow did not appear to
influence physical activity, despite the fact that colder temperatures and shorter days are associated
with reduced levels of activity [5]. On the other hand, presence of ice affects the way almost half of US
adults go about their daily activities, and compared with those under the age of 65 years, older adults
are twice as likely to report great difficulty in leaving the home in these conditions [6]. Living at higher
latitudes is also associated with having lower vitamin D levels, although colder seasons may have a
stronger negative influence than latitude [7]. Higher vitamin D levels are consistently associated with
better muscle function [8,9] in older adults and so those living in colder climates may have greater risk
for hypovitaminosis D-related functional declines.
A study of community-dwelling older adults at increased risk of falls has reported that sarcopenia
prevalence estimates may range from 3% to 26%, depending on which of the revised EWGSOP
definition’s recommended measurements are used [10]. Thus, it is difficult to compare the results of
studies that have utilised different measurements to assess muscle mass and function even when the
same operational definition is applied. These challenges are compounded by the fact that age-related
declines in muscle mass and function may vary by ethnicity within and between countries [11,12],
and that recommended cut-points for sarcopenia, which have generally been derived from Caucasian
populations, are generally not appropriate for other ethnicities [1]. These ethnic differences in muscle
mass and function need to be taken into account when exploring whether there is indeed an effect of
climate on sarcopenia prevalence in older adults.
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Using the EWGSOP’s revised algorithm, and measurements including hand grip strength and
muscle quantity assessed by bioelectrical impedance analysis (BIA), Su et al. report the prevalence of
sarcopenia in 310 adults aged 65 years and older residing in Hokkaido to be 8.1% [3]. Interestingly,
a recent study of older adults residing on the southern Japanese island of Kyushu [13] reported that
sarcopenia prevalence, determined using similar methods to identify sarcopenia cases, was between
6.6% and 7.4%, which is similar to that observed by Su et al., for the northern island of Hokkaido.
The prevalence reported in these Japanese populations is much higher than we previously observed
(1.9%) using the revised EWGSOP definition in a large population of 70-year-olds residing at a much
higher latitude (63◦), in Umea, Sweden, compared with Hokkaido (43◦) [14], but similar to that
reported in a study of older adults in Liège, Belgium (7.4%) which is also at a higher latitude (50◦) than
Hokkaido [2]. Taken together, these studies of sarcopenia, utilising current case-finding guidelines, do
not appear to indicate a latitudinal difference in prevalence amongst community-dwelling older adults.
While it does not appear that sarcopenia prevalence is greater for older adults in colder climates,
clinicians should recognise that individuals living in these regions may face greater barriers to adopting
and maintaining lifestyle behaviours that promote healthy ageing. Older adults should be reminded
that the approach with the strongest evidence for improving muscle mass, strength and function is
accessible in any climate; progressive resistance training, such as weight-lifting which can be performed
in indoor gymnasiums and clinics, is recommended as the first line therapy to manage sarcopenia [15].
Clinicians can support patients with sarcopenia to engage in individually-tailored resistance training
programs by referral to qualified professionals such as exercise physiologists.
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